HomeCompareTFFP vs EQR

TFFP vs EQR: Dividend Comparison 2026

TFFP yields 3076.92% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TFFP wins by $578804600665.46M in total portfolio value
10 years
TFFP
TFFP
● Live price
3076.92%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$578804600665.50M
Annual income
$544,023,840,488,516,100.00
Full TFFP calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — TFFP vs EQR

📍 TFFP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTFFPEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TFFP + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TFFP pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TFFP
Annual income on $10K today (after 15% tax)
$261,538.46/yr
After 10yr DRIP, annual income (after tax)
$462,420,264,415,238,660.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, TFFP beats the other by $462,420,264,415,235,400.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TFFP + EQR for your $10,000?

TFFP: 50%EQR: 50%
100% EQR50/50100% TFFP
Portfolio after 10yr
$289402300332.77M
Annual income
$272,011,920,244,259,970.00/yr
Blended yield
93.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TFFP
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-34.6
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TFFP buys
0
EQR buys
0
No recent congressional trades found for TFFP or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTFFPEQR
Forward yield3076.92%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$578804600665.50M$40.5K
Annual income after 10y$544,023,840,488,516,100.00$3,819.61
Total dividends collected$576403114825.48M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: TFFP vs EQR ($10,000, DRIP)

YearTFFP PortfolioTFFP Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$318,392$307,692.31$11,248$547.57+$307.1KTFFP
2$9,496,461$9,155,781.67$12,701$666.53+$9.48MTFFP
3$265,378,974$255,217,760.17$14,405$814.59+$265.36MTFFP
4$6,949,441,440$6,665,485,937.77$16,413$999.84+$6949.43MTFFP
5$170,564,997,752$163,129,095,411.51$18,795$1,232.92+$170564.98MTFFP
6$3,924,365,658,393$3,741,861,110,798.54$21,639$1,527.95+$3924365.64MTFFP
7$84,659,703,250,880$80,460,631,996,399.20$25,057$1,903.80+$84659703.23MTFFP
8$1,712,795,370,094,185$1,622,209,487,615,743.00$29,197$2,385.87+$1712795370.06MTFFP
9$32,505,383,342,974,930$30,672,692,296,974,148.00$34,250$3,008.70+$32505383342.94MTFFP
10$578,804,600,665,499,400$544,023,840,488,516,100.00$40,467$3,819.61+$578804600665.46MTFFP

TFFP vs EQR: Complete Analysis 2026

TFFPStock

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Full TFFP Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TFFP vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TFFP vs SCHDTFFP vs JEPITFFP vs OTFFP vs KOTFFP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.